Hepatitis C and heart transplantation: An update.
DAAs
HCV
HCV mismatch transplant
heart transplantation
outcomes
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
15
08
2023
received:
05
06
2023
accepted:
18
08
2023
medline:
11
10
2023
pubmed:
31
8
2023
entrez:
31
8
2023
Statut:
ppublish
Résumé
There are limited data regarding heart transplantation in the setting of hepatitis C virus (HCV) infection in either recipients or donors, as the practice was infrequent, given concerns of worse post-transplant outcomes. This changed dramatically after the development of highly effective HCV therapies, namely direct-acting antivirals (DAAs). Additionally, nucleic acid testing currently in use establishes more precisely the risk of HCV transmission from donors. As a result, chronic HCV infection in itself is no longer a barrier for heart transplant candidates, and the use of HCV-positive organs for HCV-infected and non-infected transplant candidates has increased dramatically. A review of the literature revealed that in the pre-DAA era, HCV seropositive heart transplant patients had a higher mortality than their seronegative counterparts. However, short-term data suggest that the differences in survival have been erased in the DAA era. Heart transplantation from HCV-viremic donors to HCV-uninfected recipients has become increasingly common as the number of deceased donors with HCV viremia has increased over the past years. Preliminary outcome reports are very encouraging, although further data are needed with regard to long-term safety. New information continues to be incorporated to optimize protocols that guide this practice.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15111Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Mudge GH, Goldstein S, Addonizio LJ, et al. 24th Bethesda Conference: cardiac transplantation: task force 3: recipient guidelines/prioritization. J Am Coll Cardiol. 1993;22:21-31.
AASLD & IDSA HCV Guidance. Kidney transplant patients. [Accessed September 1st 2022] https://www.hcvguidelines.org/unique-populations/kidney-transplant
UNOS News Bureau. Unexpected HCV donor-derived transmissions on the rise. 2019. https://unos.org/news/in-focus/unexpected-hcv-donor-derived-transmissions-on-the-rise/
Lake KD, Smith CI, LaForest SK, Allen J, Pritzker MR, Emery RW. Policies regarding the transplantation of hepatitis C-positive candidates and donor organs. J Heart Lung Transplant. 1997;16(9):917-921.
Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation Guidelines for the care of cardiac transplant candidates-2006. J Heart Lung Transplant. 2006;25(9):1024-1042.
Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016;35(1):1-23.
Huckaby LV, Seese LM, Handzel R, Wang Y, Hickey G, Kilic A. Center-level utilization of hepatitis C virus-positive donors for orthotopic heart transplantation. Transplantation. 2021;105(12):2639-2645.
Gernhofer YK, Brambatti M, Greenberg BH, Adler E, Aslam S, Pretorius V. The impact of using hepatitis c virus nucleic acid test-positive donor hearts on heart transplant waitlist time and transplant rate. J Heart Lung Transplant. 2019;38(11):1178-1188.
Altshuler PJ, Helmers MR, Schiazza AR, et al. HCV-positive allograft use in heart transplantation is associated with increased access to overdose donors and reduced waitlist mortality without compromising outcomes. J Cardiac Fail. 2022;28:32-41.
Aslam S, Grossi P, Schlendorf KH, et al>, the working group members. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: an ISHLT expert consensus statement. J Heart Lung Transplant. 2020;3(9):418-432.
Fagiuoli S, Minniti F, Pevere S, et al. HBV and HCV infections in heart transplant recipients. J Heart Lung Transplant. 2001;20(7):718-724.
Lunel F, Cadranel JF, Rosenheim M, et al. Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology. 2000;119(4):1064-1074.
Cano O, Almenar L, Martínez-Dolz L, et al. Course of patients with chronic hepatitis C virus infection undergoing heart transplantation. Transplant Proc. 2007;39(7):2353-2354.
Lin MH, Chou NK, Chi NH, et al. The outcome of heart transplantation in hepatitis C-positive recipients. Transplant Proc. 2012;44(4):890-893.
Stepanova M, Locklear T, Rafiq N, Mishra A, Venkatesan C, Younossi ZM. Long-term outcomes of heart transplant recipients with hepatitis C positivity: the data from the U.S. transplant registry. Clin Transplant. 2016;30(12):1570-1577.
Fujisaki T, Mikami T, Kuno T, Moss N, Itagaki S. Effect of hepatitis C virus infection on heart transplants in the current era. Transplantation. 2021;105(11):2482-2489.
Gasink LB, Blumberg EA, Localio AR, Desai SS, Israni AK, Lautenbach E. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA. 2006;296(15):1843-1850.
https://optn.transplant.hrsa.gov/data/view-data-reports/national-data
Colvin M, Smith JM, Ahn Y, et al. OPTN/SRTR 2019 annual data report: heart. Am J Transplant. 2021;21(2):356-440.
Humar A, Morris M, Blumberg E, et al. Nucleic acid testing (NAT) of organ donors: is the ‘best’ test the right test? A consensus conference report. Am J Transplant. 2010;10:889-899.
Organ Procurement & Transplantation Network. Guidance on PHS increased risk donor organs. https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/guidance-on-phs-increased-risk-donor-organs/
Li SS, Osho A, Moonsamy P, et al. Trends in the use of hepatitis C viremic donor hearts. J Thorac Cardiovasc Surg. 2022;163:1873-1885.
Madan S, Patel S, Vlismas P, et al. Increasing multiorgan heart transplantation with hepatitis C virus donors in the current era. J Heart Lung Transplant. 2021;40(11):1382-1386.
Ong JP, Barnes DS, Younossi ZM, et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology. 1999;30(5):1293-1298.
Haji SA, Starling RC, Avery RK, et al. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant. 2004;23(3):277-283.
Fong TL, Hou L, Hutchinson IV, Cicciarelli JC, Cho YW. Impact of hepatitis C infection on outcomes after heart transplantation. Transplantation. 2009;88(9):1137-1141.
Lee I, Localio R, Brensinger CM, et al. Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity. J Heart Lung Transplant. 2011;30(11):1266-1274.
Kumar S, Deo SV, Altarabsheh SE, et al. Effect of hepatitis C positivity on survival in adult patients undergoing heart transplantation (from the United Network for Organ Sharing Database). Am J Cardiol. 2016;118(1):132-137.
Okoh AK, Chan O, Schultheis M, et al. Association between increased-risk donor social behaviors and recipient outcomes after heart transplantation. Clin Transplant. 2020;34:e13787.
Madan S, Patel SR, Rahgozar K, et al. Utilization rates and clinical outcomes of hepatitis C positive donor hearts in the contemporary era. J Heart Lung Transplant. 2019;38:907-917.
Doulamis IP, Tzani A, Moustakidis S, Kampaktsis P, Briasoulis A. Effect of hepatitis C donor status on heart transplantation outcomes in the United States. Clin Transplant. 2021;35:e14220.
Kilic A, Hickey G, Mathier M, et al. Outcomes of adult heart transplantation using hepatitis C-positive donors. J Am Heart Assoc. 2020;9:e014495.
Bakhtiyar SS, Godfrey EL, Ahmed S, et al. Survival on the heart transplant waiting list. JAMA Cardiol. 2020;5(11):1227-1235.
Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet. 2002;359:133-135.
Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130(6):1636-1642.
Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350-1359.
Hidalgo LG, Halloran PF. Role of IFN-gamma in allograft rejection. Crit Rev Immunol. 2002;22:317-349.
Fagiuoli S, Pevere S, Minniti F, et al. Natural leukocyte interferon alfa for the treatment of chronic viral hepatitis in heart transplant recipients. Transplantation. 2003;75:982-986.
Durante-Mangoni E, Ragone E, Pinto D, et al. Outcome of treatment with pegylated interferon and ribavirin in heart transplant recipients with chronic hepatitis C. Transplant Proc. 2011;43(1):299-303.
Shafii AE, Su JW, Smedira NG, et al. The effect of recipient hepatitis C virus infection on outcomes following heart transplantation. Transplant Proc. 2010;42(5):1784-1787.
Kim E, Ko H-H, Yoshida EM. A concise review of hepatitis C in heart and lung transplantation. Can J Gastroenterol. 2011;25(8):445-448.
Liu CH, Chen YS, Wang SS, et al. Sofosbuvir-based interferon-free direct acting antiviral regimens for heart transplant recipients with chronic hepatitis C virus infection. Clin Infect Dis. 2018;66(2):289-292.
Trakroo S, Qureshi K. Successful treatment of chronic hepatitis C infection with direct-acting antivirals in a heart transplant recipient: a case report. Transplant Proc. 2015;47:2295-2297.
Mansour M, Hill L, Kerr J. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation. Transpl Infect Dis. 2018;20(6):e12972.
Lu Y-M, Yang W-L, Chang C-Y, et al. Clinical experience of patients with hepatitis C treated with direct-acting antivirals after heart transplantation. Transplant Proc. 2021;53(2):665-672.
Woolley AE, Singh SK, Goldberg HJ, et al. Heart and lung transplants from HCV-infected donors to uninfected recipients. N Engl J Med. 2019;380:1606-1617.
Gottlieb RL, Sam T, Wada SY, et al. Rational heart transplant from a hepatitis C donor: new antiviral weapons conquer the Trojan horse. J Cardiac Fail. 2017;23:765-767.
Wang JH, Gustafson SK, Skeans MA, et al. OPTN/SRTR 2018 annual data report: hepatitis C. Am J Transplant. 2020;20(s1):542-568.
Prakash K, Wainana C, Trageser J, et al. Local and regional variability in utilization and allocation of hepatitis C virus-infected hearts for transplantation. Am J Transplant. 2020;20(10):2867-2875.
Siddiqi HK, Schlendorf KH. Hepatitis C positive organ donation in heart transplantation. Curr Transplant Rep. 2021;8(4):359-367.
Raasikh T, Jamali T, Flores A, et al. Systematic review: hepatitis C viraemic allografts to hepatitis C-negative recipients in solid organ transplantation. Aliment Pharmacol Ther. 2021;54(5):571-582.
Weinfurtner K, Reddy KR. Hepatitis C viraemic organs in solid organ transplantation. J Hepatol. 2021;74(3):716-733.
Villegas-Galaviz J, Anderson E, Guglin M. Clinical outcomes of heart transplantation using hepatitis c-viremic donors: a systematic review with meta-analysis. J Heart Lung Transplant. 2022;41(4):538-549.
Yuan Q, Cui H, Leya GA, et al. Temporal trends and impact of willingness to accept organs from donors with hepatitis C virus. Transpl Int. 2021;34(12):2562-2569.
Bethea ED, Gaj K, Gustafson JL, et al. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study. Lancet Gastroenterol Hepatol. 2019;4:771-780.
Feld JJ, Cypel M, Kumar D, et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol. 2020;5:649-657.
McLean RC, Reese PP, Acker M, et al. Transplanting hepatitis C virus-infected hearts into uninfected recipients: a single-arm trial. Am J Transplant. 2019;19:2533-2542.
Reyentovich A, Gidea CG, Smith D, et al. Outcomes of the treatment with glecaprevir/pibrentasvir following heart transplantation utilizing hepatitis C viremic donors. Clin Transplant. 2020;34(9):e13989.
Smith DE, Chen S, Fargnoli A, et al. Impact of early initiation of direct-acting antiviral therapy in thoracic organ transplantation from hepatitis C virus positive donors. Semin Thorac Cardiovasc Surg. 2021;33(2):407-415.
Schlendorf KH, Zalawadiya S, Shah AS, et al. Expanding heart transplant in the era of direct-acting antiviral therapy for hepatitis C. JAMA Cardiol. 2020;5:167.
Aslam S, Yumul I, Mariski M, Pretorius V, Adler E. Outcomes of heart transplantation from hepatitis C virus-positive donors. J Heart Lung Transplant. 2019;38:1259-1267.
Morris KL, Adlam JP, Padanilam M, et al. Hepatitis C donor viremic cardiac transplantation: a practical approach. Clin Transplant. 2020;34:e13764.
Kapila N, Menon KVN, Al-Khalloufi K, et al. Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus-negative recipients: a real-world experience. Hepatology. 2020;72:32-41.
Nnani DU, Campbell A, Ajaimy M, et al. Effect of glecaprevir/pibrentasvir on weight-adjusted tacrolimus trough/dose ratios in heart and kidney transplant recipients. Transpl Infect Dis. 2021;23(5):e13716.
Hudson MR, Webb AR, Logan AT, Silverman A. Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct-acting antiviral initiation. Clin Transplant. 2021;35:e14386.
Stachel MW, Alimi M, Narula N, et al. Long-term follow-up of acute on chronic rejection in heart transplant recipients from hepatitis C viremic (NAT+) donors. Am J Transplant. 2022;22:2951-2960.
Gidea CG, Narula N, Reyentovich A, et al. Increase early acute cellular rejection events in hepatitis C-positive heart transplantation. J Heart Lung Transplant. 2020;39:1199-1207.
Madan S, Patel SR, Jorde UP. Cardiac allograft vasculopathy and secondary outcomes of hepatitis C-positive donor hearts at 1 year after transplantation. J Heart Lung Transplant. 2020;39:1318-1321.
Wen D, Du X, Dong JZ, Ma CS. Hepatitis C virus infection and risk of coronary artery disease: a meta-analysis. Eur J Intern Med. 2019;63:69-73.
Tatum R, Briasoulis A, Tchantchaleishvili V, Massey HT. Evaluation of donor heart for transplantation. Heart Fail Rev. 2022;27(5):1819-1827.
Sabra M, Ilonze O, Rao RA, Saleem K. Guglin ME. Donor substance abuse and heart transplantation outcomes. Heart Fail Rev. 2023; 28(1):207-215.
Woolley AE, Singh SK. The curious phenomenon of early cardiac allograft rejection with hepatitis C-infected donor heart transplants. J Heart Lung Transplant. 2020;39(11):1208-1209.
Goldstein BA, Thomas L, Zaroff JG, Nguyen J, Menza R, Khush KK. Assessment of heart transplant waitlist time and pre- and post-transplant failure: a mixed methods approach. Epidemiology. 2016;27:469-476.
Logan C, Yumul I, Cepeda J, et al. Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients. Am J Transplant. 2021;21:657-668.
Edmonds C, Carver A, DeClercq J, et al. Access to hepatitis C direct-acting antiviral therapy in hepatitis C-positive donor to hepatitis C-negative recipient solid-organ transplantation in a real-world setting. Am J Surg. 2022;223(5):975-982.
Elfeki MA, Romero-Marrero C, Carey WD. Heart and lung transplants from HCV-infected donors. N Engl J Med. 2019;381(10):987-988.